Recent News

• 10.22.2025 - Cassava Sciences Appoints Dawn C. Bir to the Board of Directors
• 08.25.2025 - Cassava Sciences to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
• 08.14.2025 - Cassava Reports Q2 2025 Financials Results and Provides Business Update
• 08.14.2025 - Cassava Reports Q2 2025 Financials Results and Provides Business Update
• 08.07.2025 - Cassava Sciences Appoints Dr. Joseph Hulihan as Chief Medical Officer
• 08.04.2025 - Cassava Sciences Reports Positive Preclinical Study Evaluating Simufilam for TSC-Related Epilepsy

Recent Filings

• 10.22.2025 - 4 Statement of changes in beneficial ownership of securities
• 10.22.2025 - EX-99.1 EX-99.1
• 10.22.2025 - 3 Initial statement of beneficial ownership of securities
• 10.22.2025 - 8-K Current report
• 10.02.2025 - 4 Statement of changes in beneficial ownership of securities
• 09.23.2025 - 4 Statement of changes in beneficial ownership of securities
• 09.22.2025 - 4 Statement of changes in beneficial ownership of securities
• 09.08.2025 - 8-K Current report
• 09.08.2025 - EX-99.1 EX-99.1
• 08.14.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]